Lantern Pharma (LTRN) Tops Q3 EPS by 19c

Lantern Pharma (NASDAQ: LTRN) reported Q3 EPS of ($0.29), $0.19 better than the analyst estimate of ($0.48).

For earnings history and earnings-related data on Lantern Pharma (LTRN) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Geberit AG (GEBN:SW) (GBERY) PT Raised to CHF712 at Jefferies
• Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral